CClinicalTrials.gg
RecruitingNCT07092436Updated Apr 2, 2026

Pediatric Upper-Limb Rehabilitation With PhiCube, a Modular Bilateral End-Effector Device

An interventional study of Robotic bilateral upper limb rehabilitation training in Congenital and Acquired Neuromotor Disorders and Developmental Coordination Disorder (DCD), sponsored by Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato. Recruiting at 6 sites in Italy. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
4 Years to 18 Years
Sex
All
01

Study summary

The present investigation is configured as a multicenter clinical study in a within-group pilot phase.

This study aims to investigate primarily the feasibility of use and effectiveness of a treatment for upper limb function in children aged 4 to 18 years with congenital and acquired neuromotor disorders through a new portable robotic system, called PhiCube, designed for bilateral neuromotor rehabilitation of the upper limbs in subjects with neuromotor disorders.

In order to specifically investigate also the potential impact of PhiCube on movement planning aspects, the study will also involve a small group of children aged 4 to 18 years with Developmental Coordination Disorder (DCD).

Before (PreT0 and T0) and after (T1 and T2) treatment, standardized assessment tests will be administered. Regarding the investigation objectives reported above, the primary outcome measure will be the Melbourne Assessment-2 (MA2), a standardized, valid and reliable instrument for evaluating the quality of upper limb movement in children with neurological deficits, capable of measuring four elements of movement quality: range of motion, accuracy, dexterity and fluency. As secondary outcome measures, Abilhand-Kids has been chosen, a brief questionnaire that measures 21 main daily bimanual activities completed by the parent or caregiver, and various subtests and questionnaires aimed at evaluating the neuropsychological processes involved and the effects related to auditory feedback perception.

The treatment will have a total duration of approximately 3 months and will be organized in 3 weekly sessions lasting 45 minutes each, to reach a total of 30.

Descriptive statistics of the clinical and technological variables obtained in the evaluation and rehabilitation phases will be calculated. Subsequently, treatment efficacy analyses through the robotic device are planned, comparing pre-post clinical variables. All collected data will finally be analyzed in order to compare the rehabilitative efficacy of the device with respect to the different groups of participants identified based on diagnostic profile.

02

Conditions studied

  • Congenital and Acquired Neuromotor Disorders
  • Developmental Coordination Disorder (DCD)

Browse trials for

Keywords

  • Pediatric Rehabilitation
  • Upper Limb Rehabilitation
  • Robotic Rehabilitation
  • Bilateral Training
  • Neuromotor Disorders
03

In context

Motor Skills Disorders

94 studies on the registry are indexed under Motor Skills Disorders; 24 are open to participants now.

This study's planned enrollment of 54 is above the median of 40 across 67 interventional studies indexed under Motor Skills Disorders.

Browse Motor Skills Disorders studies →

Lead sponsor

Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • For subjects with congenital and acquired neuromotor disorders:

    • Diagnosis of congenital and acquired neuromotor disorders
    • Age between 4 and 18 years at the time of recruitment
    • Modified Ashworth Scale (MAS) less than 3
    • MACS level I-IV
    • Sufficient capacity to understand the proposed activities
    • Availability to attend the facility
  • For subjects with developmental coordination disorder (DCD):

    • Diagnosis of developmental coordination disorder (DCD)
    • Age between 4 and 18 years at the time of recruitment
    • Sufficient capacity to understand the proposed activities
    • Availability to attend the facility

Exclusion criteria

Exclusion Criteria:

  • For subjects with congenital and acquired neuromotor disorders:

    • Severe sensory deficits
    • Onset of pathologies that prevent participation
    • Worsening of pre-existing comorbidities
  • For subjects with developmental coordination disorder (DCD):

    • Severe sensory deficits
    • Onset of pathologies that prevent participation
    • Worsening of pre-existing comorbidities
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    PhiCube Bilateral Upper Limb Rehabilitation

    Device: Robotic bilateral upper limb rehabilitation training

Interventions

  • DeviceRobotic bilateral upper limb rehabilitation training

    Bilateral upper limb rehabilitation using PhiCube, a modular robotic end-effector device with two motorized axes that can assist or resist patient movements. Treatment consists of 30 sessions over 3 months (3 sessions/week, 45 minutes each) combining motor training with gaming elements specifically designed for pediatric populations. The device's modular design allows customization for individual patient needs and bilateral coordination training. Sessions focus on improving range of motion, precision, dexterity, and movement fluidity through controlled, repetitive, high-intensity exercises in children aged 4-18 years with neuromotor disorders and developmental coordination disorder.

06

What researchers measure

Primary outcomes

  1. Upper limb movement quality in children with neurological deficits

    Quality of upper limb movement in children with neurological deficits, measured through Melbourne Assessment-2 (MA2), which is able to measure four elements of movement quality: range of motion, precision, dexterity and fluidity.

    Time frame: Assessed at 4 time points: - PreT0: 2 months before treatment initiation - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period - T2: 1 month after treatment completion

Secondary outcomes

  1. ABILHAND-Kids Questionnaire

    A brief questionnaire measuring 21 main bimanual daily activities. Scores are assigned by parents based on the child's difficulty in performing daily activities, with a 3-point scale (impossible, difficult, easy).

    Time frame: Assessed at 4 time points: - PreT0: 2 months before treatment initiation - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period - T2: 1 month after treatment completion

  2. Leiter-3 Sustained Attention Subtest

    A subtest of the Leiter-3 non-verbal cognitive scale that evaluates sustained visual attention through tasks of increasing complexity within a specific time period. The number of correctly selected target elements is recorded.

    Time frame: Assessed at 4 time points: - PreT0: 2 months before treatment initiation - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period - T2: 1 month after treatment completion

  3. NEPSY-II Inhibition Subtest

    Evaluates inhibitory control abilities of automatic verbal responses through administration of 3 different conditions for two different stimulus sets, requiring naming, inhibition with reversal, and alternating responses based on color.

    Time frame: Assessed at 4 time points: - PreT0: 2 months before treatment initiation - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period - T2: 1 month after treatment completion

  4. NEPSY-II Auditory Attention Subtest

    Assesses the ability to maintain sustained attention to auditory stimuli performance and inhibit automatic motor responses in two tasks of increasing complexity with incremental executive control demands.

    Time frame: Assessed at 4 time points: - PreT0: 2 months before treatment initiation - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period - T2: 1 month after treatment completion

  5. NEPSY-II Manual Posture Imitation subtest

    This subtest assesses the child's ability to accurately imitate a series of progressively complex hand and finger postures demonstrated by the examiner. The raw score is obtained by summing the number of correctly executed postures, separately recorded for the dominant and non-dominant hands. From the total raw score, a weighted score is derived, which in turn is used to calculate the standard score based on normative data.

    Time frame: Assessed at 4 time points: - PreT0: 2 months before treatment initiation - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period - T2: 1 month after treatment completion

  6. NEPSY-II Manual Motor Sequences subtest

    This subtest evaluates the child's ability to observe and reproduce sequences of hand movements demonstrated by the examiner. The sequences become progressively more complex and require the integration of motor planning, attention, and imitation abilities. The raw score is calculated by summing the number of correctly imitated sequences. From the total raw score, a weighted score is derived, which is then converted into a standard score based on normative data.

    Time frame: Assessed at 4 time points: - PreT0: 2 months before treatment initiation - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period - T2: 1 month after treatment completion

  7. NEPSY-II Arrow subtest

    This subtests evaluates the ability to judge line orientation considering direction, distance, orientation, and angularity. The task requires the integration of visual attention, orientation discrimination, and mental rotation. The raw score is obtained by summing the number of correct responses across all items. From this total raw score, a weighted score is calculated and then converted into a standard score based on age-specific normative data.

    Time frame: Assessed at 4 time points: - PreT0: 2 months before treatment initiation - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period - T2: 1 month after treatment completion

  8. NEPSY-II Route Finding subtest

    This subtest assesses the ability to use a small schematic map to locate targets on a larger schematic map. The raw score corresponds to the number of correctly identified routes. From this raw score, a weighted score is derived and then transformed into a standard score using normative tables based on the child's age.

    Time frame: Assessed at 4 time points: - PreT0: 2 months before treatment initiation - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period - T2: 1 month after treatment completion

  9. BRIEF P/2 Questionnaire

    Parent-administered questionnaire evaluating executive functions in daily life contexts. Parents rate behaviors on a 3-point Likert scale based on frequency over the past six months.

    Time frame: Assessed at 4 time points: - PreT0: 2 months before treatment initiation - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period - T2: 1 month after treatment completion

  10. Usability questionnaire

    Custom questionnaire administered to stakeholders (children and operators) at treatment completion to investigate system usability.

    Time frame: T1: Immediately after completing the treatment period

  11. Acceptability questionnaire

    Custom questionnaire administered to stakeholders (children and operators) at treatment completion to investigate system acceptability.

    Time frame: T1: Immediately after completing the treatment period

  12. Compliance questionnaire

    Custom questionnaire administered to stakeholders (children and operators) at treatment completion to investigate child and operator compliance.

    Time frame: T1: Immediately after completing the treatment period

  13. Movement smoothness

    Measures of how continuous and even a movement is, without sudden stops or changes in speed. It is measured by the normalized jerk.

    Time frame: - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period

  14. Trajectory error

    Measures the error made by one limb in following a proposed trajectory via the screen.

    Time frame: - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period

  15. Bilateral coordination

    Measures coordination between limbs in performing the same movement simultaneously by calculating the difference between axes coordinates.

    Time frame: - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period

  16. Audio Feedback Effect Evaluation

    Assessment of how audio feedback influences motivational and satisfaction aspects through three interaction conditions (no feedback, reward feedback, help feedback) using VAS scales for fun and engagement, adapted In-game Questionnaire, and open-ended questions about the child's experience.

    Time frame: - T0: Immediately before starting PhiCube treatment - T1: Immediately after completing the treatment period

07

Study locations

6 of 6 sites recruiting
  • IRCCS Eugenio Medea
    Bosisio Parini, LC 23842, Italy
    Recruiting
  • IRCCS Fondazione Stella Maris
    Calambrone, PI 56128, Italy
    Recruiting
  • Fondazione Don Gnocchi - Centro S. Maria al Mare
    Salerno, SA 84131, Italy
    • Marco Germanotta, PhD · Contact · mgermanotta@dongnocchi.it · +39.089.334425
    • Irene Giovanna Aprile, PhD · Principal investigator
    Recruiting
  • IRCCS Istituto Giannina Gaslini
    Genova, 16147, Italy
    Recruiting
  • Fondazione Don Gnocchi IRCCS - Centro Santa Maria Nascente
    Milan, 20148, Italy
    • Angela Cavalagli, MD · Contact · acavalagli@dongnocchi.it · +39.02.40308279
    • Angela Cavalagli, MD · Principal investigator
    Recruiting
  • IRCCS Fondazione Mondino
    Pavia, 27100, Italy
    • Sabrina Signorini, MD · Contact · +39.0382.380233
    • Sabrina Signorini, MD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07092436
Lead sponsor
Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato
Collaborators
IRCCS Fondazione Stella Maris, IRCCS Eugenio Medea, Fondazione Don Carlo Gnocchi ETS, IRCCS Fondazione Istituto Neurologico Mondino Pavia, Ospedale IRCCS G. Gaslini di Genova
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Nov 17, 2025
Primary completion
Oct 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Apr 2, 2026

Study contacts

Matteo Malosio, PhD
Contact
matteo.malosio@cnr.it
+39.0341.235.0203
Giuseppina Sgandurra, PhD
study chair · IRCCS Fondazione Stella Maris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion